

pIRES Vector Map and Multiple Cloning Sites (MCS). Unique restriction sites are in bold. The Xmal/Smal sites can be treated as unique sites for cloning purposes.

Description

pIRES is a mammalian expression vector that allows high level expression of two genes of interest from the same bicistronic mRNA transcript. The vector contains the encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES) flanked by two multiple cloning sites (MCS A and B), an arrangement that allows cap-independent translation of the gene cloned into MCS B (1–3). pIRES utilizes a partially disabled IRES sequence (1) that reduces the rate at which the gene cloned into MCS B is translated relative to that of MCS A.

Expression of the bicistronic transcript is driven by the constitutively active cytomegalovirus immediate early promoter ($P_{CMV | E}$), located upstream of MCS A. An intervening sequence (IVS) known to enhance the stability of mRNA (4) is located between $P_{CMV | E}$ and MCS A, and is efficiently spliced out following transcription. SV40 polyadenylation signals downstream of MCS B direct proper processing of the 3' end of the mRNA. Bacteriophage T7 and T3 promoters are located upstream of MCS A and downstream of MCS B, respectively. pIRES includes a neomycin resistance gene (Neo^r) to aid in the selection of transfected cells. Neo^r is expressed from the SV40 enhancer/promoter, and a synthetic polyadenylation signal directs proper processing of the 3' end of the Neo^r mRNA. The SV40 origin allows for replication in mammalian cells expressing the SV40 T antigen. The vector also contains an ampicillin resistance gene (Amp^r), and a ColE1 origin of replication for selection and propagation in *E. coli*, and an f1 origin for single-stranded DNA production. (PR852529; published 20 May, 2008)



United States/Canada 800.662.2566 Asia Pacific +1.650.919.7300 Europe +33.(0)1.3904.6880 Japan +81.(0)77.543.6116

Clontech Laboratories, Inc. A Takara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

pIRES

Use

Genes cloned into either MCS must contain ATG start codons. pIRES and derivatives can be introduced into mammalian cells by any standard transfection method. Transformed cells can be selected by growth in medium containing the antibiotic G418. Sense or antisense RNA can be transcribed from the T7 and T3 promoters, respectively.

Location of features

• *P*_{CMV IE}:

CMV IE enhancer: 1–659 CMV IE promoter: 669–750

- Intervening sequence (IVS): 890–1022
- T7 RNA polymerase promoter: 1067–1085
- Multiple cloning site A: 1085–1107
- IRES sequence: 1130–1725
- Multiple cloning site B: 1737-1763
- T3 RNA polymerase promoter: 1771–1792 (complementary)
- SV40 polyadenylation signal: 1802–2023
- f1 origin of replication: 2118-2573
- Neo^r expression cassette: 2637-4004

SV40 enhancer/early promoter: 2637–3054 SV40 origin of replication: 2953–3018 Neo^r structural gene: 3098–3892 Start codon (ATG): 3098–3100 Stop codon: 3890–3892 Synthetic polyadenylation signal: 3956–4004

• Ampicillin resistance (β -lactamase) gene: 4415–5275

Start codon (ATG): 4415–4417 Stop codon (TAA): 5273–5275

Propagation in *E. coli*

- Suitable host strains: DH5 α , HB101, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) in *E. coli* hosts.
- E. coli replication origin: ColE1
- Copy number: low

References

- 1. Rees, S., et al. (1996) BioTechniques 20(1):102–110.
- 2. Jackson, R. J., et al. (1990) Trends Biochem. Sci. 15(12):477–483.
- 3. Jang, S. K., et al. (1990) J. Virol. 62(8):2636–2643.
- 4. Huang, M.T. F. & Gorman, C. M. (1990) Nucleic Acids Res. 18(4):937–947

Note: The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

CMV Sequence:

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2008 Clontech Laboratories, Inc.